Cellular Biomedicine Group

136 articles about Cellular Biomedicine Group

• CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

  1/12/2022

  Cellular Biomedicine Group Inc. announced that the Food and Drug Administration granted C-CAR039, a novel autologous bi-specific CAR-T therapy targeting both CD19 and CD20 antigens, both Regenerative Medicine Advanced Therapy Designation and Fast Track Designation for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma.

• CBMG Receives FDA Clearance of IND Application for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

  12/13/2021

   Cellular Biomedicine Group Inc. (CBMG or the "Company"), today announced that the Food and Drug Administration (FDA) granted clearance of the Investigational New Drug (IND) application to proceed with the Phase 1b clinical development of its chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD20 (C-CAR039).

• 

  Trio of Biopharmas Generates Over $500 Million for AI, Oncology Innovation

  10/1/2021

  ​This week, three global biopharmaceutical companies received over half a billion dollars to support research and development initiatives in the treatment of rare and deadly diseases. 

• Cellular Biomedicine Group to Present at Chinese Biopharmaceutical Association-USA Annual Conference

  8/26/2020

   Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, is scheduled for a presentation at the 25th Annual Conference of the Chinese Biopharmaceutical Association-USA (CBA) to be held online August 29-30, 2020.

• Kaskela Law LLC Announces Investigation of Cellular Biomedicine Group, Inc. (CBMG) and Encourages CBMG Shareholders to Contact the Firm

  8/14/2020

   Kaskela Law LLC announces that it is investigating Cellular Biomedicine Group, Inc. ("Cellular Biomedicine") (Nasdaq: CBMG) on behalf of the company's shareholders.  On August 12, 2020 , Cellular Biomedicine announced that it had entered into a definitive agreement whereby each currently outstanding share of the company's common

• Cellular Biomedicine Group (CBMG) Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

  8/12/2020

  Cellular Biomedicine Group, Inc. announced today that it has signed a definitive merger agreement to be acquired by a newly-formed entity formed on behalf of a consortium consisting of Bizuo Liu and certain other members of CBMG management...

• Cellular Biomedicine Group (CBMG) Hosts R&D Showcase and Provides Updates to Clinical Programs

  7/13/2020

  Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, provided an overview and update of clinical and pre-clinical programs currently being researched and develo

• Cellular Biomedicine Group (CBMG) to Host Investor R&D Showcase Highlighting Updates to Clinical Programs

  6/30/2020

  Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced it will host a virtual R&D Showcase at 8:00 AM Eastern Standard Time on Monday, July 13, 2020.

• Cellular Biomedicine Group (CBMG) Announces Results of 2020 Annual Meeting of Stockholders

  6/29/2020

   Cellular Biomedicine Group Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the voting results of its 2020 Annual Meeting of Stockholders, held on June 26, 2020 in 

• Cellular Biomedicine Group (CBMG) Presents Poster of TCRs Targeting AFP-Positive Liver Cancer at AACR Annual Meeting

  6/22/2020

   Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today presented a poster during the 2020 American Association for Cancer Research (AACR) annual meeting to be held

• Cellular Biomedicine Group (CBMG) Announces 2020 Annual Meeting of Stockholders

  5/26/2020

  Cellular Biomedicine Group Inc. has announced that the 2020 Annual Meeting of Stockholders will be held at 9:00 a.m. Eastern Standard Time on Friday, June 26, 2020, at Aloft Long Island City – Manhattan View, 27-45 Jackson Avenue, Long Island City, New York 11101.

• Cellular Biomedicine Group to Report First Quarter 2020 Results on May 6, 2020

  5/1/2020

  Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it will release its financial results for the first quarter ended March 31, 2020 after the market closes on Wednesday, May 6, 2020.

• Cellular Biomedicine Group Announces Engagement of Independent Advisors by Special Committee

  12/30/2019

  There is no formal timetable for the Special Committee process for evaluating potential strategic alternatives.

• Cellular Biomedicine Group Presents First Clinical Data of IIT Phase 1 Trial of C-CAR088, a Novel BCMA CAR-T, at the 61st Annual Meeting of the American Society of Hematology

  12/7/2019

  Five Patients were included in the analysis; all five patients showed clinical improvement in as early as two weeks

• Cellular Biomedicine Group Announces Receipt of a Preliminary Non-Binding "Going Private" Proposal

  11/11/2019

  The Board formed a special committee comprised of independent, disinterested directors to evaluate strategic alternatives.

• Cellular Biomedicine Group Reports Third Quarter of 2019 Financial Results and Business Highlights

  11/6/2019

  Cellular Biomedicine Group Inc., a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, reported its financial results and business highlights for the third quarter of 2019.

• Cellular Biomedicine Group's ReJoin® Therapy Receives Stem Cell Drug Application Acceptance For Phase II Clinical Trials by China NMPA

  9/28/2019

  Cellular Biomedicine Group, Inc. announced that a drug application* for its off-the-shelf autologous adipose-derived mesenchymal progenitor cell ReJoin® therapy for Knee Osteoarthritis has been accepted for a Phase II clinical trial in China.

• Cellular Biomedicine Group Hosts Meeting with Investigators to Launch AlloJoin® Knee Osteoarthritis Phase II Clinical Trial

  9/12/2019

  Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced that on September 11, 2019, the Company held a meeting with investigators in Shanghai to launch the Phase II clinical trial for AlloJoin®, an "off-the-shelf" allogenic human adipose-derived mesenchymal progenitor cell therapy product targeting Knee Osteoarthritis (KOA).

• Cellular Biomedicine Group to Present at Baird's 2019 Global Healthcare Conference

  8/29/2019

  Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), today announced that Derrick Li, Head of Strategy for the Company, will present at Baird's 2019 Global Healthcare Conference to be held at the InterContinental New York Barclay in New York, NY on Thursday, September 5, 2019 at 9:40am ET.

• Cellular Biomedicine Group to Report Second Quarter 2019 Results on August 6, 2019

  7/23/2019

  Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that it will release its financial results for the second quarter ended June 30, 2019 after the market closes on Tuesday, August 6, 2019.